Company news
Xenetic Biosciences, Inc. news in 2020
Xenetic Biosciences, Inc.'s news releases, calls and decks from 2020, newest first.
Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
December 13, 2020
Xenetic Biosciences, Inc. Announces $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
December 9, 2020
Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology
December 8, 2020
Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 12, 2020
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 6th Annual Israel Conference
November 4, 2020
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 8, 2020
Xenetic Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 12, 2020
Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Two Key Appointments
July 29, 2020
Xenetic Biosciences, Inc. Provides Development Update for Its Personalized CAR T Platform Technology, XCART(TM)
June 30, 2020
Xenetic Biosciences, Inc. Announces Collaboration with Pharmsynthez and Multiple Academic Institutions in Russia and Belarus to Advance Development of XCART(TM) Platform
June 15, 2020
Xenetic Biosciences, Inc. to Present at the Virtual Investor Fireside Chat Series
June 7, 2020
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART(TM) Platform
May 18, 2020
Xenetic Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 13, 2020
Xenetic Biosciences, Inc. to Present at the April 2020 Virtual Investor Summit
April 14, 2020
Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update
March 26, 2020
Xenetic Biosciences' Webcast Replay from Noble Capital Markets' 16th Annual Investor Conference Presentation Now Available
February 26, 2020
Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board
February 25, 2020
Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board
February 12, 2020
Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference
February 10, 2020